ClearPoint Neuro, Inc. reported an insider ownership change involving R. John Fletcher, a non-employee director of the company, with a transaction date of July 1, 2026. The filing indicates that Fletcher received shares of ClearPoint Neuro common stock as compensation for director fees owed to him. According to the explanatory note, the shares were issued under ClearPoint Neuro’s Seventh Amended and Restated 2013 Incentive Compensation Plan and in accordance with the company’s amended and restated Non-Employee Director Compensation Plan. The issuance was made in payment of fees rather than as an open-market purchase or sale. The shares were valued at the closing price of ClearPoint Neuro’s common stock on June 30, 2026, the trading day immediately preceding the reported issuance date. The document does not provide the number of shares issued, the per-share closing price used for the issuance, the transaction code, or Fletcher’s beneficial ownership total after the transaction in the text provided. As a result, the filing confirms the nature and timing of the equity compensation but does not allow calculation of the dollar value of the stock award or the size of Fletcher’s post-transaction ownership position. The report was signed on July 6, 2026, by Danilo D’Alessandro under power of attorney for R. John Fletcher. The action matters because it reflects ClearPoint Neuro’s practice of compensating non-employee directors with company equity, aligning director compensation with shareholder value while also modestly increasing insider ownership through plan-based stock issuance.